All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
On April 19, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to polatuzumab vedotin, an antibody-drug conjugate, in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisolone) for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL)-not otherwise specified or high-grade B-cell lymphoma who have an International Prognostic Index score of ≥2.1
Polatuzumab vedotin in combination with bendamustine and rituximab was previously granted accelerated approval by the U.S. FDA for the treatment of relapsed/refractory (R/R) DLBCL after at least two prior lines of therapy. Following the FDA Oncologic Drugs advisory committee (ODAC) vote (recently discussed by Grzegorz Nowakowski on the Lymphoma Hub) and results from the phase III POLARIX study (NCT03274492), the FDA has granted approval to polatuzumab vedotin plus R-CHP as a first-line treatment for DLBCL.1 In the POLARIX study, improvements in progression-free survival were seen with polatuzumab vedotin in combination with R-CHP compared with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), with the R-CHP combination showing a 27% reduced risk of disease progression, relapse, or death.1 The adverse event profiles were comparable (Table 1). The most common AEs were peripheral neuropathy, nausea, fatigue, diarrhea, constipation, alopecia, and mucositis; the most common Grade 3–4 AEs were lymphopenia and neutropenia.1
Table 1. Safety profile of polatuzumab vedotin combined with R-CHP vs R-CHOP*
AE, adverse event; R-CHP, rituximab, cyclophosphamide, doxorubicin, and prednisolone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. |
||
AE |
Polatuzumab vedotin + R-CHP |
R-CHOP |
---|---|---|
Grade 3–4 AEs |
57.7% |
57.5% |
Serious AEs |
34.0% |
30.6% |
Grade 5 AEs |
3.0% |
2.3% |
AEs leading to dose reduction |
9.2% |
13.0% |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?